GxPinnacle Logo

Pharmacovigilance Regulatory Expectations

What Do Inspectors Check for Pharmacovigilance KPI Governance and Oversight?

Pharmacovigilance systems must monitor operational performance through defined key performance indicators (KPIs). Regulators expect organisations to implement governance frameworks defining KPI ownership, targets, thresholds, oversight meetings, and corrective actions when performance deviates.

Founders, CEOs & MDsPV LeadsQA/ComplianceScientists tasked with documentation

The short version

What teams need to understand

  • Pharmacovigilance systems should monitor operational performance through defined KPIs aligned with regulatory obligations.
  • KPIs should cover structural, process, and outcome indicators to provide a complete view of PV system performance.
  • Governance structures must define KPI ownership, targets, thresholds, and review cadence.
  • KPI monitoring should provide early warning signals for compliance risks and operational weaknesses.
  • Performance deviations must trigger escalation, investigation, and corrective actions where necessary.
  • Inspection-ready evidence should demonstrate that PV performance metrics are actively monitored and reviewed.

Regulatory expectation

What regulators expect

Each expectation should be supported by controlled documentation, traceable records, clear ownership, and evidence that the process works in practice.

  • Pharmacovigilance systems must monitor operational performance through defined metrics.
  • KPIs should cover structural, process, and outcome aspects of PV activities.
  • Ownership and governance responsibilities must be clearly defined.
  • KPI thresholds must trigger escalation and corrective action when breached.
  • KPI monitoring must support continuous improvement of the PV system.

Why it matters

What this means in practice

Inspectors assess whether pharmacovigilance systems actively monitor operational performance through defined KPIs and governance oversight. They typically review KPI definitions, ownership structures, performance thresholds, dashboards, and oversight mechanisms used to ensure ongoing compliance and quality in PV activities.

Questions this page answers

What KPIs should be monitored in pharmacovigilance?
What governance framework do regulators expect for PV KPIs?
How do inspectors evaluate pharmacovigilance performance monitoring?
What documentation proves KPI oversight during PV inspections?
How should pharmacovigilance KPIs be structured?
How do inspectors verify PV KPI governance?
What metrics should pharmacovigilance systems track?
How should PV system performance be monitored?
What evidence demonstrates pharmacovigilance governance oversight?
What inspection findings occur for weak KPI monitoring?

Inspection evidence

Evidence teams should be able to show

Pharmacovigilance KPI Management SOP

  • Defined KPI governance framework
  • Roles and responsibilities for KPI ownership
  • Definitions of structural, process, and outcome indicators
  • Documentation of KPI targets and thresholds
  • Defined review cadence for KPI monitoring

KPI Master Tracker

  • List of defined pharmacovigilance KPIs
  • Assigned KPI owners and responsible functions
  • Defined data sources for KPI measurement
  • Defined targets and escalation thresholds
  • Review frequency and reporting structure

PV KPI Dashboard

  • Monthly KPI dashboard reports
  • RAG (Red-Amber-Green) performance indicators
  • Trend charts for PV operational metrics
  • Dashboard exports presented during governance meetings

Governance Structure Documentation

  • PV governance committee terms of reference
  • Defined responsibilities of QPPV and PV leadership
  • Escalation pathways for KPI deviations
  • Documented ownership of KPI monitoring activities

Oversight Meeting Records

  • Monthly PV KPI review meeting agendas
  • Meeting minutes documenting KPI discussion
  • Recorded action items for KPI deviations
  • Follow-up evidence showing closure of actions

Regulatory Basis (Primary Sources)

  • GVP Module I - pharmacovigilance systems must include performance monitoring and quality management processes
  • GVP Module IV - PV audits and compliance oversight expectations
  • ICH E2D - post-approval safety reporting principles supporting PV system performance monitoring
  • ICH E2E - pharmacovigilance planning guidance supporting safety system performance monitoring
  • MHRA Good Pharmacovigilance Practice (GPvP) guidance - expectations for PV system governance and oversight
  • FDA pharmacovigilance guidance - expectations for monitoring safety system performance and regulatory compliance

Typical Inspection Questions (What Inspectors Ask)

  • What KPIs do you monitor for pharmacovigilance performance?
  • How are KPI targets and thresholds defined?
  • Who owns the KPI governance framework?
  • Show evidence that KPI performance is reviewed by management.
  • What actions are taken when KPI performance falls below target?

Common failure patterns

No defined KPI framework for monitoring pharmacovigilance system performance.
KPIs exist but ownership and responsibilities are unclear.
Performance thresholds are not defined or not monitored consistently.
KPIs are reported but not reviewed or acted upon by governance bodies.
KPI monitoring is disconnected from CAPA or improvement processes.

What good looks like

  • A defined KPI framework covering structural, process, and outcome indicators.
  • Clear ownership and governance of KPI monitoring activities.
  • Defined targets and thresholds aligned with regulatory expectations.
  • Regular review of KPI performance by PV leadership.
  • KPI monitoring linked to continuous improvement and CAPA processes.

How teams operationalise it

  • Define a pharmacovigilance KPI framework aligned with regulatory expectations.
  • Assign ownership for each KPI and document responsibilities.
  • Define targets and escalation thresholds for each metric.
  • Implement systems for collecting KPI data from operational sources.
  • Ensure KPI results are reviewed regularly by PV leadership.
  • Integrate KPI monitoring with CAPA and continuous improvement processes.

From expectation to working control

Find the documentation that supports this work

Review the related toolkit to understand its purpose, included files, and how it supports this regulatory expectation.

Browse pharmacovigilance toolkitsView related toolkit

Frequently asked questions

Why are KPIs important in pharmacovigilance systems?

KPIs provide measurable indicators of PV system performance, allowing organisations to detect compliance risks early and ensure safety processes operate effectively.

What types of KPIs should a pharmacovigilance system include?

PV systems typically monitor structural KPIs (system infrastructure), process KPIs (execution of PV activities), and outcome KPIs (overall compliance and safety performance).

What are examples of pharmacovigilance KPIs inspectors expect?

Examples include ICSR reporting timeliness, case quality scores, signal evaluation timelines, PSUR submission compliance rates, CAPA closure rates, and training completion metrics.

Who is responsible for pharmacovigilance KPI governance?

KPI governance is typically overseen by PV leadership and the QPPV, with defined ownership assigned to relevant functional leads.

How often should PV KPIs be reviewed?

KPIs are commonly reviewed monthly within PV governance meetings and periodically reported to senior management.

How do inspectors verify pharmacovigilance KPI oversight?

Inspectors typically request KPI dashboards, governance meeting minutes, and evidence that KPI deviations triggered corrective actions or CAPA processes.

Source boundary

Regulatory sources

These primary sources inform this structured interpretation. Always confirm current requirements against the original source and the requirements applicable to your organisation, product, and jurisdiction.

European Medicines Agency (EMA)

  • Good pharmacovigilance practices (GVP)

    View source

  • Guideline on good pharmacovigilance practices (GVP) - Module I

    View source

International Council for Harmonisation (ICH)

  • Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting (E2D)

    View source

  • Pharmacovigilance Planning (E2E)

    View source

U.S. Food and Drug Administration (FDA)

  • Postmarketing Safety Reporting for Human Drug and Biological Products

    View source

UK MHRA (GOV.UK)